Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome.

摘要: Idiopathic hypereosinophilic syndrome (HES) is a myeloproliferative disorder characterized by persistent eosinophilia and organ involvement. Different treatments have been investigated in HES with modest success. It has suggested that imatinib active HES. We treated 9 patients 100 mg daily. Doses for without response after 4 weeks were increased to 400 Prior therapy had failed 7 patients. Five responded: achieved sustained complete remission lasting median of 12+ (range, 9+ 36+ weeks), 1 transient response. One patient died remission. Responses occurred within therapy; only responder required an increase dose Three nonresponders respond dose. Toxicity was minimal. conclude effective